CLINICAL TRIALS PROFILE FOR AIR POLYMER-TYPE A
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Air Polymer-type A
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT04026945 ↗ | Sustained Release Lidocaine for Treatment of Scrotal Pain | Completed | University of British Columbia | Phase 1/Phase 2 | 2019-10-31 | In this study, the investigators are testing a new formulation of lidocaine for its suitability in managing chronic scrotal pain (CSCP). The new formulation ST-CP is a lidocaine sustained-release formulation and is expected to provide pain relief over 4 weeks. Currently, the drug lidocaine is not available as an injectable slow-release formulation and chronic scrotal pain patients are often left untreated. |
| New Formulation | NCT05193227 ↗ | Sustained Release Lidocaine for the Treatment of Postoperative Pain | Recruiting | University of British Columbia | Phase 2 | 2021-10-27 | In this study, the investigators are testing a new formulation of lidocaine for its suitability in managing postoperative pain after pelvic surgery. The new formulation ST-01 is a sustained release lidocaine formulation and is expected to provide pain relief over multiple days. Currently, the drug lidocaine is not available as an injectable slow-release formulation. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Air Polymer-type A
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003876 ↗ | Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma | Completed | Barrett Cancer Center | Phase 1 | 1999-04-01 | RATIONALE: Internal radiation uses high-energy radiation to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining internal radiation therapy with chemotherapy implants may kill remaining tumor cells following surgery. PURPOSE: Phase I trial to study the effectiveness of internal radiation therapy plus carmustine implants in treating patients who have recurrent or refractory malignant glioma. |
| NCT00003878 ↗ | Carmustine Implants in Treating Patients With Brain Metastases | Completed | National Cancer Institute (NCI) | Phase 2 | 2002-04-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of implanted carmustine wafers in treating patients who have brain metastases and who are undergoing surgery to remove the tumor. |
| NCT00003878 ↗ | Carmustine Implants in Treating Patients With Brain Metastases | Completed | New Approaches to Brain Tumor Therapy Consortium | Phase 2 | 2002-04-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of implanted carmustine wafers in treating patients who have brain metastases and who are undergoing surgery to remove the tumor. |
| NCT00004315 ↗ | Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease | Unknown status | Children's Hospital Medical Center, Cincinnati | Phase 2 | 1995-11-01 | OBJECTIVES: I. Compare the bioavailability of polymer-coated and buffered ursodiol (ursodeoxycholic acid) to unmodified ursodiol in patients with cystic fibrosis-associated liver disease or chronic cholestatic liver disease. II. Compare the differences in pruritus, weight gain, and liver function for both treatments. |
| NCT00004315 ↗ | Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease | Unknown status | National Center for Research Resources (NCRR) | Phase 2 | 1995-11-01 | OBJECTIVES: I. Compare the bioavailability of polymer-coated and buffered ursodiol (ursodeoxycholic acid) to unmodified ursodiol in patients with cystic fibrosis-associated liver disease or chronic cholestatic liver disease. II. Compare the differences in pruritus, weight gain, and liver function for both treatments. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Air Polymer-type A
Condition Name
Clinical Trial Locations for Air Polymer-type A
Trials by Country
Clinical Trial Progress for Air Polymer-type A
Clinical Trial Phase
Clinical Trial Sponsors for Air Polymer-type A
Sponsor Name
